(Q34409791)

English

What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

0 references

1 reference

Europe PubMed Central

What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

0 references

0 references

systematic review

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Charlotte Manisty

object named as

Charlotte H Manisty

2

0 references

author name string

Judith A Finegold

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Anthony J Barron

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Darrel P Francis

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

publication date

12 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

European Journal of Preventive Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

464-474

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Risks associated with statin therapy: a systematic overview of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Statin-related adverse events: a meta-analysis

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Nonspecific medication side effects and the nocebo phenomenon

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information.

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Effect of pravastatin on outcomes after cardiac transplantation.

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantation: results of a randomised double blind placebo controlled study

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Risk of incident diabetes among patients treated with statins: population based study.

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

External validity of randomised controlled trials: "to whom do the results of this trial apply?".

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Effect of a high dose of simvastatin on muscle mitochondrial metabolism and calcium signaling in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Nocebo effects, patient-clinician communication, and therapeutic outcomes

1 reference

https://api.crossref.org/works/10.1177%2F2047487314525531

21 January 2018

Identifiers

10.1177/2047487314525531

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34409791&oldid=1959028681"